What was the outcome of Recordati's board vote on the CVC and GBL takeover offer, and how did independent directors respond?

Six out of Recordati's 10 board members voted that the €51.29 per share offer by CVC Capital Partners and Groupe Bruxelles Lambert was 'fair', while four independent directors dissented, deeming the offer 'inadequate' and 'not fair', though they acknowledged its strategic rationale and potential benefits of delisting.

What is the value and structure of the offer for Recordati, and what strategic rationale did the board cite in supporting it?

The offer is a €10.7 billion cash bid to take Recordati private at €51.29 ($58.80) per share, made in May 2024; the board cited potential benefits of operating as a privately held company, including greater flexibility to pursue 'long-term strategic initiatives' and acquisition opportunities.

Italy's Recordati says board finds CVC, GBL offer 'fair' as independent directors dissent

Jul 15, 2026

Recordati's board voted 6-4 to accept CVC and GBL's €10.7 billion takeover offer as fair, despite four independent directors dissenting over valuation concerns. The proposed delisting aligns with broader consolidation trends in Italy's pharmaceutical sector.

reuters

2026-05-21

CVC, GBL Launch 10.7 Billion Euro Takeover Offer for Italy's Recordati

2026-07-15

Italy's Recordati says board finds CVC, GBL offer 'fair' as independent directors dissent

Italy's Recordati says board finds CVC, GBL offer 'fair' as independent directors dissent

FAQ